A Cystic Fibrosis Diagnosis No Longer Automatically Qualifies for Make-A-Wish
https://pixabay.com/en/little-girl-praying-people-wishing-1894125/

A Cystic Fibrosis Diagnosis No Longer Automatically Qualifies for Make-A-Wish

  Children with cystic fibrosis (CF) born between 1995 and 1999 had an estimated life expectancy of 32 years. Advances in both research and treatment have contributed to increased life…

Continue Reading A Cystic Fibrosis Diagnosis No Longer Automatically Qualifies for Make-A-Wish
Is This Pharmaceutical Company Putting Profits Over the Lives of Cystic Fibrosis Patients?
source: shutterstock.com

Is This Pharmaceutical Company Putting Profits Over the Lives of Cystic Fibrosis Patients?

The advocacy group Just Treatment recently published a press release titled 'BREAKING: Cystic Fibrosis Patients Launch Global Challenge to Vertex Monopoly on CF Drugs.' Vertex Pharmaceuticals has taken the lead…

Continue Reading Is This Pharmaceutical Company Putting Profits Over the Lives of Cystic Fibrosis Patients?

Cutting-Edge Cystic Fibrosis Therapies Are Overpriced. This Campaign is Calling for Greater Access

In recent years, treatment options for cystic fibrosis, a rare disease, have increased significantly in number and in effectiveness. However, many of the most effective treatments, developed by Vertex Pharmaceuticals,…

Continue Reading Cutting-Edge Cystic Fibrosis Therapies Are Overpriced. This Campaign is Calling for Greater Access
Newborn Screenings Miss Cystic Fibrosis in Non-White Newborns
https://pixabay.com/en/people-portrait-girl-black-girl-3194027/

Newborn Screenings Miss Cystic Fibrosis in Non-White Newborns

Newborn screening is a public health program in which infants are screened for various metabolic, genetic, and developmental disorders shortly after birth. Through newborn screening, doctors may identify potential disorders…

Continue Reading Newborn Screenings Miss Cystic Fibrosis in Non-White Newborns
ICYMI: Cystic Fibrosis Drug TRIKAFTA Accepted for Priority Review in Canada for Patients Aged 6-11
source: pixabay.com

ICYMI: Cystic Fibrosis Drug TRIKAFTA Accepted for Priority Review in Canada for Patients Aged 6-11

  In June 2021, Health Canada approved TRIKAFTA (elexacaftor/tezacaftor/ivacaftor) for patients with cystic fibrosis (CF), with at least one F508del mutation, aged 12+. According to a news release from late…

Continue Reading ICYMI: Cystic Fibrosis Drug TRIKAFTA Accepted for Priority Review in Canada for Patients Aged 6-11